External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Slides:



Advertisements
Similar presentations
Contemporary practice of radiotherapy post radical prostatectomy at a tertiary referral centre in Australia Introduction  Adverse features on histopathology.
Advertisements

Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Steven Joniau Filip Ameye
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Volume 155, Issue 3, Pages (March 1996)
Volume 195, Issue 5, Pages (May 2016)
Nat. Rev. Urol. doi: /nrurol
Decipher Prostate, Decipher Bladder and Decipher GRID
Sanjay Kalra, MD, James P. Utz, MD, Eric S. Edell, MD, Robert L
Managing Cancer Pain: Basic Principles and Invasive Treatments
The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients 
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Volume 49, Issue 2, Pages (February 2006)
Apollo Gleneagles Hospitals,
Advances in the Treatment of Metastatic Prostate Cancer
Volume 53, Issue 5, Pages (May 2008)
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Volume 52, Issue 4, Pages (October 2007)
William L. Lanier, MD  Mayo Clinic Proceedings 
Food Allergy: Common Causes, Diagnosis, and Treatment
Treatment of Alcohol Withdrawal in Hospitalized Patients
Nomograms for Bladder Cancer
Evaluation and Medical Management of Benign Prostatic Hyperplasia
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
Obsessive Compulsive Disorder: A Clinical Update
What is New in Hormone Therapy for Prostate Cancer in 2007?
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Management: What Does the Future Hold?
Volume 67, Issue 6, Pages (June 2015)
George Dailey, MD  Mayo Clinic Proceedings 
Volume 71, Issue 5, Pages (May 2017)
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Volume 64, Issue 6, Pages (December 2013)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
LESLIE M. RAINWATER, M.D., WILLIAM R. MORGAN, M.D. 
Thomas M. Pisansky, MD, Douglas G. Gold, MD, PhD, Keith M
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Optimising Hormone Therapy in Advanced Disease
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Photodynamic Therapy for Early Stage Central Type of Lung Cancer
Long-Term Hormonal Therapy: Who Would Benefit?
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Axel Heidenreich  European Urology Supplements 
Highlighting Unmet Needs: Real Patients, Difficult Choices
Volume 53, Issue 6, Pages (June 2008)
Management of Prostate Cancer: Global Strategies
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Medical Treatment of Overactive Bladder: In Response
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Sanjay Kalra, MD, James P. Utz, MD, Eric S. Edell, MD, Robert L
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Axel Heidenreich  European Urology Supplements 
Managing Cancer Pain: Basic Principles and Invasive Treatments
Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders  Martin Benesch, MD, H. Joachim.
Acute and Chronic Seizures in Patients Older Than 60 Years
Presentation transcript:

External Beam Radiotherapy as Curative Treatment of Prostate Cancer Thomas M. Pisansky, MD  Mayo Clinic Proceedings  Volume 80, Issue 7, Pages 883-898 (July 2005) DOI: 10.4065/80.7.883 Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Nomogram for predicting the probability of prostate cancer metastasis after external beam radiotherapy based on prognostic factors. From Kattan et al.12 Reprinted with permission from the American Society of Clinical Oncology. Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Results of treatment for patients with at least 1 unfavorable prognostic factor (T2b-T2c, Gleason score =7, or prostate-specific antigen >10 ng/mL) according to therapeutic modality and radiotherapy (RT) dose level. RP = radical prostatectomy. From Kupelian et al.16 Reprinted with permission from the American Society of Clinical Oncology. Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 Prostate cancer-specific mortality after external beam radiotherapy in 2370 patients with localized prostate cancer according to low-risk (T1c-T2a, Gleason score =6, or prostate-specific antigen [PSA] =10 ng/mL), intermediate-risk (T2b, Gleason score 7, or PSA 10.1-20.0 ng/mL), and high-risk (T2c, Gleason scores 8-10, or PSA >20 ng/mL) groups; differences between groups were significant. From D'Amico et al.36 Reprinted with permission from the American Society of Clinical Oncology. Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 4 Overall survival (4839 patients) and cause-specific survival (3547 patients) after external beam radiotherapy in patients with localized prostate cancer (left) and cause-specific survival (right) according to low-risk (T1b-T2a, Gleason score =6, and prostate-specific antigen [PSA] =10 ng/mL), intermediate-risk ([T1b-T2a, Gleason score =7, or PSA >10 but =20 ng/mL] or [T2b-T2c, Gleason score =7, or PSA =20 ng/mL]), and high-risk (Gleason scores 8-10 or PSA >20 ng/mL) groups.39 Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 5 Quality of life among patients more than 1 year after undergoing external beam radiotherapy (RT) (147 patients), brachytherapy (84), or prostatectomy (671) for prostate cancer or among controls (112) without prostate cancer. Raw values represent the mean of the treatment group, with higher values indicating better quality of life. The difference between brachytherapy and controls was significant only in the prostate cancer-related domain; no other significant differences were identified. Data from Wei et al.55 Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 6 Quality-of-life uniscale symptom scores before and at 3, 12, and 24 months after external beam radiotherapy in 182 patients with localized prostate cancer. Values represent the mean of the group on a scale of 0 (minimal) to 100 (maximum); higher values represent greater symptom bother. From Talcott et al.60 Reprinted with permission from the American Society of Cinical Oncology. Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 7 Results of treatment for patients with at least 1 unfavorable histopathologic factor (involved surgical margin, extraprostatic extension, seminal vesicle invasion) after prostatectomy. RT = radiotherapy. From Urol Clin North Am,92 with permission from Elsevier. Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 8 Progression-free probability 4 years after external beam radiotherapy (RT) among patients treated for postoperative biochemical relapse. ADT = androgen deprivation therapy; PFP = progression-free probability; PSA = prostate-specific antigen; PSADT = PSA doubling time. Values in parentheses are 95% confidence intervals. From JAMA,100 with permission. Mayo Clinic Proceedings 2005 80, 883-898DOI: (10.4065/80.7.883) Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions